Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

Revenue and test growth outpaced, but losses widened and profitability remains unproven.

What the company is saying

Adaptive Biotechnologies frames the quarter as 'exceptional,' emphasizing MRD segment growth and increased test volumes. The narrative spotlights a 33% year-over-year MRD revenue increase and a 43% rise in clonoSEQ test volume, positioning these as evidence of operational momentum. Management highlights the $345 million convertible notes raise and repayment of the OrbiMed agreement as moves that 'fortify' the balance sheet and enable strategic flexibility. The announcement stresses the planned separation of the MRD and Immune Medicine businesses, suggesting this will unlock long-term value, but does not provide supporting financial detail. While the company raises MRD revenue guidance for 2026, it omits any profitability guidance or detailed segment-level margins. The tone is confident and forward-looking, but relies on superlatives and aspirational claims not fully substantiated by disclosed numbers.

What the data suggests

Second quarter 2026 revenue reached $71.6 million, with the MRD business accounting for 92% and growing 33% year-over-year. clonoSEQ test volume hit 36,111, up 43% from the prior year, indicating strong operational throughput. Despite these gains, net loss widened to $39.9 million from $25.6 million, and operating expenses increased to $87.3 million from $83.9 million. Adjusted EBITDA loss narrowed to $0.7 million from $7.2 million, showing some operational leverage but not enough to offset rising costs. Immune Medicine revenue fell 40% to $5.4 million, and there is no guidance for this segment. The $345 million convertible notes offering boosted liquidity to $371.7 million, but the company remains unprofitable. Full-year MRD revenue guidance was raised to $268–278 million, implying 26–31% growth, but no evidence is provided that this will translate to profitability. The data is clear on revenue and cash position but lacks granularity on segment margins or path to break-even.

Analysis

The announcement uses positive language to describe the quarter as 'exceptional' and highlights growth in MRD revenue and test volume. However, while revenue and operational growth are clearly disclosed, the company remains unprofitable, with net loss increasing year-over-year ($39.9M loss vs $25.6M prior). The claim of 'expanding growth and profitability in MRD' is not substantiated by segment-level profit data—only revenue and test volume are provided. The $345M convertible notes offering is a significant capital event, but its benefits are described in terms of 'increased financial flexibility' and future strategic priorities, not immediate earnings impact. Forward-looking statements, such as raised MRD revenue guidance and the planned business separation, are present but not excessive. The gap between narrative and evidence is most apparent in the use of superlatives and claims of long-term value creation without supporting profitability metrics.

Risk flags

• ●Rising net losses and operating expenses signal that revenue growth is not translating into profitability. The net loss increased to $39.9 million from $25.6 million year-over-year, while operating expenses also rose, suggesting ongoing cash burn and potential future dilution or financing needs.
• ●Lack of segment-level profitability data for MRD and Immune Medicine limits visibility into whether growth is sustainable or value-accretive. The company discloses revenue and test volumes, but omits operating income or margin figures for its core segments.
• ●The planned separation of MRD and Immune Medicine businesses introduces execution risk. No timeline, cost estimate, or projected financial impact is provided, making it difficult to assess whether the split will unlock value or create disruption.
• ●Heavy reliance on capital markets is evident from the $345 million convertible notes raise. While liquidity is strong at $371.7 million, persistent losses could erode this buffer, especially if operating expenses remain high and Immune Medicine revenue continues to decline.

Bottom line

Adaptive Biotechnologies delivered strong MRD revenue and test growth, but losses widened and profitability remains elusive. The company’s narrative leans heavily on operational momentum and strategic moves like the business separation and debt raise, yet omits critical details on segment profitability or a clear path to break-even. Liquidity is robust following the $345 million notes offering, but rising expenses and declining Immune Medicine revenue highlight ongoing financial risks. The planned business split could reshape the company, but with no timeline or quantified benefits, its impact is speculative. For investors, the key takeaway is that while top-line growth is real, the absence of profit metrics and persistent losses mean the investment case hinges on future execution, not current financial strength. More granular disclosure on segment margins and a credible path to profitability would be needed to materially improve the outlook.

Announcement summary

(NASDAQ:ADPT) Adaptive Biotechnologies Corporation reported revenue of $71.6 million for the quarter ended June 30, 2026. The MRD business contributed 92% of revenue and grew 33% versus the second quarter of 2025, with clonoSEQ test volume increasing 43% to 36,111 tests delivered. The company completed a $345 million zero-coupon convertible senior notes offering and repaid the OrbiMed Purchase Agreement. Operating expenses for the second quarter of 2026 were $87.3 million, and net loss was $39.9 million, compared to $25.6 million for the same period in 2025. Cash, cash equivalents and marketable securities totaled $371.7 million as of June 30, 2026. Adaptive Biotechnologies announced plans to pursue a separation of its MRD and Immune Medicine businesses. The company expects full year 2026 MRD revenue to be between $268 million and $278 million, implying annual growth of 26% to 31%.

Disagree with this article?